The Impact of Metastable Lutetium-177 on a Nuclear Medicine Department

3021 null Objectives: null null In the United States, Lutetium-177 is being used to treat patient’s with gastro-entero-pancreatic neuroendocrine tumors with the FDA approved radiopharmaceutical Lutathera, which is manufactured by Advanced Accelerator Applications. In addition, Radiomedix, is manufacturing Lutetium-177-PSMA to treat patients with metastatic prostate cancer as part of a phase III clinical trial which is run by Endocyte. Each...